Safety assessment of a solid lipid curcumin particle preparation: Acute and subchronic toxicity studies

Food and Chemical Toxicology

Volumn 49, Issue 8, 2011, Pages 1834-1842

  Dadhaniya, Paresh ^a   Patel, Chintan ^a   Muchhara, Jayesh ^a   Bhadja, Nilesh ^a   Mathuria, Neeta ^a   Vachhani, Kapil ^a   Soni, Madhu G ^b  

^a Cadila Pharmaceutical Ltd   (India)

^b Soni and Associates Inc   (United States)

Author keywords

Curcumin; Food ingredient; Safety; Toxicity; Turmeric

Indexed keywords

CURCUMIN; SOLID LIPID CURCUMIN PARTICLE; UNCLASSIFIED DRUG;

ACUTE TOXICITY; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CHRONIC TOXICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; EYE EXAMINATION; FEMALE; FOOD INTAKE; HISTOPATHOLOGY; LD 50; MALE; MOUSE; NONHUMAN; ORGAN WEIGHT; RAT; SUBCHRONIC TOXICITY; TOXICITY TESTING; WEIGHT GAIN;

ACUTE TOXICITY TESTS; ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; BODY WEIGHT; CURCUMA; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOLOGIC TESTS; LETHAL DOSE 50; LIPIDS; MALE; MICE; NO-OBSERVED-ADVERSE-EFFECT LEVEL; ORGAN SIZE; PLANT EXTRACTS; RATS; RATS, WISTAR; TOXICITY TESTS, CHRONIC; URINALYSIS; WEIGHT GAIN;

CURCUMA LONGA; MUS; RATTUS; RATTUS NORVEGICUS;

EID: 79958762040     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2011.05.001     Document Type: Article

References (22)

1. Aggarwal B.B., Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol. Sci. 2008, 30:85-94.
2. Aggarwal B., Kumar A., Bharti A. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003, 23(1A):363-398.
3. Aggarwal B., Bhatt I., Ichikawa H., Ahn K., Sethi G., Sandur S. Curcumin-biological and medicinal properties. Turmeric: The Genus Curcuma 2007, vol. 1:297-368. Taylor and Francis Group, Boca Raton, FL.
4. Ammon H.P., Wahl M.A. Pharmacology of Curcuma longa. Planta Med. 1991, 57:1-7.
5. Chattopadhyay I., Biswas K., Bandyopadhyay U., Banerjee R.K. Turmeric and curcumin: biological actions and medicinal applications. Current Sci. 2004, 87:44-50.
6. Cheng A.L., Hsu C.H., Lin J.K., Hsu M.M., Ho Y.F., Shen T.S., Ko J.Y., Lin J.T., Lin B.R., Ming-Shiang W., Yu H.S., Jee S.H., Chen G.S., Chen T.M., Chen C.A., Lai M.K., Pu Y.S., Pan M.H., Wang Y.J., Tsai C.C., Hsieh C.Y. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001, 21:2895-2900.
7. Daybe, F.V., 1870. Uber Curcumin. den Farbstoff der Curcumawurzzel Ber 3, 609 (cited in Shishodia et al., 2008).
8. Dhillon N., Aggarwal B., Newman R., Wolff R., Kunnumakkara A., Abbruzzese J., Ng C., Badmaev V., Kurzrock R. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin. Cancer Res. 2008, 14:4491-4499.
9. Goel A., Kunnumakkara A.B., Aggarwal B.B. Curcumin as "Curecumin": from kitchen to clinic. Biochem. Pharmacol. 2008, 75:787-809.
10. Gota V.S., Maru G.B., Soni T.G., Gandhi T.R., Kochar N., Agarwal M.G. Safety and pharmacokinetics of a solid lipid curcumin particle formulation in osteosarcoma patients and healthy volunteers. J. Agric. Food Chem. 2010, 58(4):2095-2099.
11. Govindarajan V.S. Turmeric: chemistry, technology, and quality. CRC Crit. Rev. Food Sci. Nutr. 1980, 12:199-301.
12. Kuttan R., Bhanumathy P., Nirmala K., George M. Potential anticancer activity of turmeric (Curcuma longa). Cancer Lett. 1985, 29(2):197-202.
13. Lilja, H.S., Hagopian, M., Esber, H.J., Fleischman, R.W., Russfield, A.B., Tiedemann, K.M., 1983. Report on the subchronic toxicity by dosed feed of turmeric oleoresin (C60015) in Fischer 344 rats and B6C3F1 mice. EGG Mason Research Institute, Report No. MRI-NTP 11-83-22, Submitted to WHO by the National Institutes of Health, Research Triangle Park, NC, USA (cited in: WHO, 1987).
14. NTP, 1993. National Toxicology Program. Toxicology and carcinogenesis studies of turmeric oleoresin (CAS No. 8024-37-1) (Major Component 79-85% curcumin, CAS No. 458-37-7) in F344/N rats and B6C3F1 mice (Feed studies). Technical Report Series No. 427, NIH, Publication No. 93-3158. US Department of Health and Human Services, Public Health Service, National Institutes of Health, Research Triangle Park, NC.
15. Ravindranath V., Chandrasekhara N. Metabolism of curcumin - studies with [3H]-curcumin. Toxicology 1982, 22:337-344.
16. Shehzad A., Wahid F., Lee Y.S. Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch. Pharm. (Weinheim) 2010, 343:489-499.
17. Shishodia S., Misra K., Aggarwal B. Turmeric as cure-cumin: promises, problems, and solutions. Dietary Modulation of Cell Signaling Pathways 2008, 91-136. CRC Press. Y. Surh, Z. Dong, E. Cadenas, L. Packer (Eds.).
18. Shoba G., Joy D., Thangam J., Majeed M., Rajendran R., Srinivas P.S.S.R. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998, 64:353-356.
19. Sikora E., Scapagnini G., Barbagallo M. Curcumin, inflammation, ageing and age-related diseases. Immun. Ageing 2010, 7(1):1.
20. Wahlstom B., Blennow G. A study on the fate of curcumin in the rat. Acta Pharmacol. Toxicol. 1978, 43:86-92.
21. WHO, 1996. WHO Food Additives Series 35. Toxicological Evaluation of Certain Food Additives and Contaminants. Curcumin. Report available online at: http://www.inchem.org/documents/jecfa/jecmono/v21je06.htm.
22. Zhou, H., Beevers, C.S., Huang, S., 2010. The targets of curcumin. Curr. Drug Targets. 2010 October 18 (Epub ahead of print).